Compare RRGB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | ADCT |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.6M | 136.1M |
| IPO Year | 2002 | 2019 |
| Metric | RRGB | ADCT |
|---|---|---|
| Price | $7.50 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $9.00 | $7.75 |
| AVG Volume (30 Days) | 165.7K | ★ 1.1M |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,315,014,000.00 | $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $2.46 | $0.78 |
| 52 Week High | $8.26 | $4.98 |
| Indicator | RRGB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.13 | 30.93 |
| Support Level | $6.26 | $0.78 |
| Resistance Level | $8.26 | $1.17 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 91.01 | 6.12 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).